Quick Answer
TRINITY BIOTECH PLC reported R&D Expense of $4.54 million for fiscal year 2024.
TRINITY BIOTECH PLC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $4.54M | +3.7% |
| 2023 | $4.38M | +5.8% |
| 2022 | $4.14M | -8.0% |
| 2021 | $4.50M | -11.5% |
| 2020 | $5.08M | -4.6% |
| 2019 | $5.33M | -0.8% |
| 2018 | $5.37M | -5.1% |
| 2017 | $5.66M | +12.2% |
| 2016 | $5.04M | -0.6% |
| 2015 | $5.07M | — |
- TRINITY BIOTECH PLC showed an increase of +3.7% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2024 period, TRINITY BIOTECH PLC’s r&d expense has declined by 10.4% (from $5.07 million to $4.54 million).
- The most recent figure is from TRINITY BIOTECH PLC’s fiscal year 2024 report (Form 20-F), filed with the SEC on May 16, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: